BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 38614108)

  • 1. RAB32 Ser71Arg in autosomal dominant Parkinson's disease: linkage, association, and functional analyses.
    Gustavsson EK; Follett J; Trinh J; Barodia SK; Real R; Liu Z; Grant-Peters M; Fox JD; Appel-Cresswell S; Stoessl AJ; Rajput A; Rajput AH; Auer R; Tilney R; Sturm M; Haack TB; Lesage S; Tesson C; Brice A; Vilariño-Güell C; Ryten M; Goldberg MS; West AB; Hu MT; Morris HR; Sharma M; Gan-Or Z; Samanci B; Lis P; Periñan MT; Amouri R; Ben Sassi S; Hentati F; ; Tonelli F; Alessi DR; Farrer MJ
    Lancet Neurol; 2024 Jun; 23(6):603-614. PubMed ID: 38614108
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A pathogenic variant in RAB32 causes autosomal dominant Parkinson's disease and activates LRRK2 kinase.
    Gustavsson EK; Follett J; Trinh J; Barodia SK; Real R; Liu Z; Grant-Peters M; Fox JD; Appel-Cresswell S; Stoessl AJ; Rajput A; Rajput AH; Auer R; Tilney R; Sturm M; Haack TB; Lesage S; Tesson C; Brice A; Vilariño-Güell C; Ryten M; Goldberg MS; West AB; Hu MT; Morris HR; Sharma M; Gan-Or Z; Samanci B; Lis P; Tocino T; Amouri R; Sassi SB; Hentati F; ; Tonelli F; Alessi DR; Farrer MJ
    medRxiv; 2024 Jan; ():. PubMed ID: 38293014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNM3 and genetic modifiers of age of onset in LRRK2 Gly2019Ser parkinsonism: a genome-wide linkage and association study.
    Trinh J; Gustavsson EK; Vilariño-Güell C; Bortnick S; Latourelle J; McKenzie MB; Tu CS; Nosova E; Khinda J; Milnerwood A; Lesage S; Brice A; Tazir M; Aasly JO; Parkkinen L; Haytural H; Foroud T; Myers RH; Sassi SB; Hentati E; Nabli F; Farhat E; Amouri R; Hentati F; Farrer MJ
    Lancet Neurol; 2016 Nov; 15(12):1248-1256. PubMed ID: 27692902
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study.
    Ross OA; Soto-Ortolaza AI; Heckman MG; Aasly JO; Abahuni N; Annesi G; Bacon JA; Bardien S; Bozi M; Brice A; Brighina L; Van Broeckhoven C; Carr J; Chartier-Harlin MC; Dardiotis E; Dickson DW; Diehl NN; Elbaz A; Ferrarese C; Ferraris A; Fiske B; Gibson JM; Gibson R; Hadjigeorgiou GM; Hattori N; Ioannidis JP; Jasinska-Myga B; Jeon BS; Kim YJ; Klein C; Kruger R; Kyratzi E; Lesage S; Lin CH; Lynch T; Maraganore DM; Mellick GD; Mutez E; Nilsson C; Opala G; Park SS; Puschmann A; Quattrone A; Sharma M; Silburn PA; Sohn YH; Stefanis L; Tadic V; Theuns J; Tomiyama H; Uitti RJ; Valente EM; van de Loo S; Vassilatis DK; Vilariño-Güell C; White LR; Wirdefeldt K; Wszolek ZK; Wu RM; Farrer MJ;
    Lancet Neurol; 2011 Oct; 10(10):898-908. PubMed ID: 21885347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies.
    Wile DJ; Agarwal PA; Schulzer M; Mak E; Dinelle K; Shahinfard E; Vafai N; Hasegawa K; Zhang J; McKenzie J; Neilson N; Strongosky A; Uitti RJ; Guttman M; Zabetian CP; Ding YS; Adam M; Aasly J; Wszolek ZK; Farrer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2017 May; 16(5):351-359. PubMed ID: 28336296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.
    Healy DG; Falchi M; O'Sullivan SS; Bonifati V; Durr A; Bressman S; Brice A; Aasly J; Zabetian CP; Goldwurm S; Ferreira JJ; Tolosa E; Kay DM; Klein C; Williams DR; Marras C; Lang AE; Wszolek ZK; Berciano J; Schapira AH; Lynch T; Bhatia KP; Gasser T; Lees AJ; Wood NW;
    Lancet Neurol; 2008 Jul; 7(7):583-90. PubMed ID: 18539534
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LRP10 genetic variants in familial Parkinson's disease and dementia with Lewy bodies: a genome-wide linkage and sequencing study.
    Quadri M; Mandemakers W; Grochowska MM; Masius R; Geut H; Fabrizio E; Breedveld GJ; Kuipers D; Minneboo M; Vergouw LJM; Carreras Mascaro A; Yonova-Doing E; Simons E; Zhao T; Di Fonzo AB; Chang HC; Parchi P; Melis M; Correia Guedes L; Criscuolo C; Thomas A; Brouwer RWW; Heijsman D; Ingrassia AMT; Calandra Buonaura G; Rood JP; Capellari S; Rozemuller AJ; Sarchioto M; Fen Chien H; Vanacore N; Olgiati S; Wu-Chou YH; Yeh TH; Boon AJW; Hoogers SE; Ghazvini M; IJpma AS; van IJcken WFJ; Onofrj M; Barone P; Nicholl DJ; Puschmann A; De Mari M; Kievit AJ; Barbosa E; De Michele G; Majoor-Krakauer D; van Swieten JC; de Jong FJ; Ferreira JJ; Cossu G; Lu CS; Meco G; Cortelli P; van de Berg WDJ; Bonifati V;
    Lancet Neurol; 2018 Jul; 17(7):597-608. PubMed ID: 29887161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LRRK2 binds to the Rab32 subfamily in a GTP-dependent manner
    McGrath E; Waschbüsch D; Baker BM; Khan AR
    Small GTPases; 2021 Mar; 12(2):133-146. PubMed ID: 31552791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systematic rare variant analyses identify RAB32 as a susceptibility gene for familial Parkinson's disease.
    Hop PJ; Lai D; Keagle PJ; Baron DM; Kenna BJ; Kooyman M; Shankaracharya ; Halter C; Straniero L; Asselta R; Bonvegna S; Soto-Beasley AI; ; Wszolek ZK; Uitti RJ; Isaias IU; Pezzoli G; Ticozzi N; Ross OA; Veldink JH; Foroud TM; Kenna KP; Landers JE
    Nat Genet; 2024 Jun; ():. PubMed ID: 38858457
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of LRRK2 mutations on the cholinergic system in manifest and premanifest stages of Parkinson's disease: a cross-sectional PET study.
    Liu SY; Wile DJ; Fu JF; Valerio J; Shahinfard E; McCormick S; Mabrouk R; Vafai N; McKenzie J; Neilson N; Perez-Soriano A; Arena JE; Cherkasova M; Chan P; Zhang J; Zabetian CP; Aasly JO; Wszolek ZK; McKeown MJ; Adam MJ; Ruth TJ; Schulzer M; Sossi V; Stoessl AJ
    Lancet Neurol; 2018 Apr; 17(4):309-316. PubMed ID: 29456161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Penetrance estimate of LRRK2 p.G2019S mutation in individuals of non-Ashkenazi Jewish ancestry.
    Lee AJ; Wang Y; Alcalay RN; Mejia-Santana H; Saunders-Pullman R; Bressman S; Corvol JC; Brice A; Lesage S; Mangone G; Tolosa E; Pont-Sunyer C; Vilas D; Schüle B; Kausar F; Foroud T; Berg D; Brockmann K; Goldwurm S; Siri C; Asselta R; Ruiz-Martinez J; Mondragón E; Marras C; Ghate T; Giladi N; Mirelman A; Marder K;
    Mov Disord; 2017 Oct; 32(10):1432-1438. PubMed ID: 28639421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of genetic risk loci and causal insights associated with Parkinson's disease in African and African admixed populations: a genome-wide association study.
    Rizig M; Bandres-Ciga S; Makarious MB; Ojo OO; Crea PW; Abiodun OV; Levine KS; Abubakar SA; Achoru CO; Vitale D; Adeniji OA; Agabi OP; Koretsky MJ; Agulanna U; Hall DA; Akinyemi RO; Xie T; Ali MW; Shamim EA; Ani-Osheku I; Padmanaban M; Arigbodi OM; Standaert DG; Bello AH; Dean MN; Erameh CO; Elsayed I; Farombi TH; Okunoye O; Fawale MB; Billingsley KJ; Imarhiagbe FA; Jerez PA; Iwuozo EU; Baker B; Komolafe MA; Malik L; Nwani PO; Daida K; Nwazor EO; Miano-Burkhardt A; Nyandaiti YW; Fang ZH; Obiabo YO; Kluss JH; Odeniyi OA; Hernandez DG; Odiase FE; Tayebi N; Ojini FI; Sidranksy E; Onwuegbuzie GA; D'Souza AM; Osaigbovo GO; Berhe B; Osemwegie N; Reed X; Oshinaike OO; Leonard HL; Otubogun FM; Alvarado CX; Oyakhire SI; Ozomma SI; Samuel SC; Taiwo FT; Wahab KW; Zubair YA; Iwaki H; Kim JJ; Morris HR; Hardy J; Nalls MA; Heilbron K; Norcliffe-Kaufmann L; ; ; ; ; Blauwendraat C; Houlden H; Singleton A; Okubadejo NU;
    Lancet Neurol; 2023 Nov; 22(11):1015-1025. PubMed ID: 37633302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic analysis and natural history of Parkinson's disease due to the LRRK2 G2019S variant.
    Kmiecik MJ; Micheletti S; Coker D; Heilbron K; Shi J; Stagaman K; Filshtein Sonmez T; Fontanillas P; Shringarpure S; Wetzel M; Rowbotham HM; Cannon P; Shelton JF; Hinds DA; Tung JY; ; Holmes MV; Aslibekyan S; Norcliffe-Kaufmann L
    Brain; 2024 Jun; 147(6):1996-2008. PubMed ID: 38804604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Functional variants in the
    Hui KY; Fernandez-Hernandez H; Hu J; Schaffner A; Pankratz N; Hsu NY; Chuang LS; Carmi S; Villaverde N; Li X; Rivas M; Levine AP; Bao X; Labrias PR; Haritunians T; Ruane D; Gettler K; Chen E; Li D; Schiff ER; Pontikos N; Barzilai N; Brant SR; Bressman S; Cheifetz AS; Clark LN; Daly MJ; Desnick RJ; Duerr RH; Katz S; Lencz T; Myers RH; Ostrer H; Ozelius L; Payami H; Peter Y; Rioux JD; Segal AW; Scott WK; Silverberg MS; Vance JM; Ubarretxena-Belandia I; Foroud T; Atzmon G; Pe'er I; Ioannou Y; McGovern DPB; Yue Z; Schadt EE; Cho JH; Peter I
    Sci Transl Med; 2018 Jan; 10(423):. PubMed ID: 29321258
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genomewide Association Studies of LRRK2 Modifiers of Parkinson's Disease.
    Lai D; Alipanahi B; Fontanillas P; Schwantes-An TH; Aasly J; Alcalay RN; Beecham GW; Berg D; Bressman S; Brice A; Brockman K; Clark L; Cookson M; Das S; Van Deerlin V; Follett J; Farrer MJ; Trinh J; Gasser T; Goldwurm S; Gustavsson E; Klein C; Lang AE; Langston JW; Latourelle J; Lynch T; Marder K; Marras C; Martin ER; McLean CY; Mejia-Santana H; Molho E; Myers RH; Nuytemans K; Ozelius L; Payami H; Raymond D; Rogaeva E; Rogers MP; Ross OA; Samii A; Saunders-Pullman R; Schüle B; Schulte C; Scott WK; Tanner C; Tolosa E; Tomkins JE; Vilas D; Trojanowski JQ; ; Uitti R; Vance JM; Visanji NP; Wszolek ZK; Zabetian CP; Mirelman A; Giladi N; Orr Urtreger A; Cannon P; Fiske B; Foroud T
    Ann Neurol; 2021 Jul; 90(1):76-88. PubMed ID: 33938021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LRRK2 Gly2019Ser penetrance in Arab-Berber patients from Tunisia: a case-control genetic study.
    Hulihan MM; Ishihara-Paul L; Kachergus J; Warren L; Amouri R; Elango R; Prinjha RK; Upmanyu R; Kefi M; Zouari M; Sassi SB; Yahmed SB; El Euch-Fayeche G; Matthews PM; Middleton LT; Gibson RA; Hentati F; Farrer MJ
    Lancet Neurol; 2008 Jul; 7(7):591-4. PubMed ID: 18539535
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 and Rab GTPases.
    Pfeffer SR
    Biochem Soc Trans; 2018 Dec; 46(6):1707-1712. PubMed ID: 30467121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson's disease.
    Heckman MG; Labbé C; Kolicheski AL; Soto-Beasley AI; Walton RL; Valentino RR; Brennan ER; Johnson PW; Baheti S; Sarangi V; Ren Y; Uitti RJ; Wszolek ZK; Ross OA
    Parkinsonism Relat Disord; 2021 Feb; 83():22-30. PubMed ID: 33454605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Leucine-Rich Repeat Kinase (LRRK2) Genetics and Parkinson's Disease.
    Monfrini E; Di Fonzo A
    Adv Neurobiol; 2017; 14():3-30. PubMed ID: 28353276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LRRK2 haplotype-sharing analysis in Parkinson's disease reveals a novel p.S1761R mutation.
    Lorenzo-Betancor O; Samaranch L; Ezquerra M; Tolosa E; Lorenzo E; Irigoyen J; Gaig C; Pastor MA; Soto-Ortolaza AI; Ross OA; Rodríguez-Oroz MC; Valldeoriola F; Martí MJ; Luquin MR; Perez-Tur J; Burguera JA; Obeso JA; Pastor P
    Mov Disord; 2012 Jan; 27(1):146-51. PubMed ID: 22038903
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.